8/27/2016 1 Hypophosphatasia and Alkaline Phosphatase – What Are The Clinical Issues? Center for Metabolic Bone Disease and Molecular Research, Shriners Hospital for Children; and Michael P. Whyte MD Division of Bone and Mineral Diseases, Department of Internal Medicine, Washington University School of Medicine; St. Louis, Missouri, U.S.A. Alkaline Phosphatase: We’ve Been Assaying It For 93 Years, But What Does It Do? (Role Revealed in Hypophosphatasia) Disclosure Honoraria, Travel, and Research Grant Support; Alexion Pharmaceuticals, Cheshire, CT asfotase alfa (Strensiq ™)* * biologic for pediatric-onset hypophosphatasia Robert Robison, Ph.D (1883-1941) C. R. Harington Obituary Notices of Fellows of the Royal Society, Vol. 3, No. 10 (Dec., 1941), pp. 929-939 “Bone Phosphatase”
23
Embed
Hypophosphatasia and Alkaline Phosphatasebetterbones.org/wp-content/uploads/2016/08/3_HPP-and-ALP-PDF.pdf · Hypophosphatasia and Alkaline Phosphatase ... Pathogenesis Phosphoethanolamine
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
8/27/2016
1
Hypophosphatasia andAlkaline Phosphatase –
What Are The Clinical Issues?
Center for Metabolic Bone Disease and Molecular Research,Shriners Hospital for Children;
and
Michael P. Whyte MD
Division of Bone and Mineral Diseases, Department of Internal Medicine,Washington University School of Medicine;
St. Louis, Missouri, U.S.A.
Alkaline Phosphatase:
We’ve Been Assaying It For 93 Years,But What Does It Do?
Causes of Hypophosphatasemia• Hypophosphatasia • Zn++ or Mg++ Deficiency• Familial Benign? • Cushing’s Syndrome• Pernicious or Profound Anemia • Milk-Alkali Syndrome• Hypothyroidism • Celiac Disease• Vitamin C Deficiency • Massive Transfusion• Osteogenesis Imperfecta, Type II* • Cleidocranial Dysostosis*• Wilson’s Disease (hemalytic anemia) • Cardiac Bypass Surgery• Vitamin D Intoxication • Improperly Collected Blood• Inappropriate Reference Range (e.g., EDTA, oxalate)• Clofibrate Therapy • Radioactive Heavy Metals• Starvation • Multiple Myeloma• Hypoparathyroidism • Achondroplasia• ERT in post-menopausal women
TNSALP (ALPL)mutation analysis
Pathogenesis
Phosphoethanolamine
(PEA)
Inorganic Pyrophosphate
(PPi)
Pyridoxal 5/-Phosphate
(PLP)
NH2CH2CH2 O P
OH
OH
O
O P
OH
OH
O P
OH
OH
N
CH2 O P
OH
OH
O
CHO
HO
H3C
O
Natural Substrates for TNSALP
Vitamin B6
8/27/2016
11
• No symptoms of Vitamin B6toxicity or deficiency
• Normal tissue levels ofVitamin B6 metabolites
• Normal urinary levels of thedegradation product, 4-pyridoxic acid
• Normal response to L-tryptophanchallenge
Normal Vitamin B6 Status inMost Hypophosphatasia Patients
PL levels arenormal in all butthe most severe
HPP (low)
Vitamin B6
Metabolism
ProteinN
C
EthN P
8/27/2016
12
PPi
PPi
Phase 2 Mineralization
Chondrocalcinosis
Calcium PyrophosphateDihydrate
Pyrophosphate Arthropathy
TREATMENT ?
Whyte et. al, J Peds 101(3):379
8/27/2016
13
Whyte et. al, J Peds 101:379, 1982
Can we increase ALP
activity directly in bone?
JBMR 18: 624-36, 2003
8/27/2016
14
JCE&M 92: 2923-30, 2007
JCE&M 92: 1203-08, 2007
11/046/04
ALP Targeted To Bone
D10 D10
TNSALP dimer
IgG1 Fc
Courtesy Dr. Marc D. McKee
Asfotase Alfa
Courtesy Dr. Marc D. McKee
8/27/2016
15
IV to Adult WT Mouse
Millan et al. (2008) J Bone Miner Res 23:781
Asfotase Alfa for Life-ThreateningHypophosphatasia
Radiographic,respiratory,
andfunctional
improvements.
PHASE I/II
March 8, 2012
N Engl J Med. 366:904-13, 2012
8/27/2016
16
Infant Study
Month 21Baseline
First Patient
Patient 2 (Infantile HPP)
Baseline 3/4 months 2 ½ months
Duration Treatment
9 Weeks
Patient 3 (Perinatal HPP)
Baseline
Age 2 years
8/27/2016
17
2 years of treatment
3 years oftreatment
7 years oftreatment
• Treatment ≥3 years well tolerated.
• Infants and children with life threatening HPP showedsignificant improvement in skeletal mineralization, onaverage at 3 months, and sustained over 3 years
• Nearly all required some respiratory support either atbaseline, or early in the study, but only a single patientrequired respiratory support (supplemental O2) at lastassessment
• Survival was 90%.
Summary
Simmons J et al. Poster presented at American College ofMedical Genetics and Genomics National Meeting, Tampa, FL.March 11, 2016
Adverse Events
Events, n
Patients, n (%)
Total events 11 (100%)URI 67 7 (64%)Craniosynostosis 12 7 (64%)
Pyrexia 20 7 (64%)
Pneumonia 14 7 (64%)
Otitis media 19 6 (55%)
Vomiting 13 6 (55%)
Constipation 7 6 (55%)
Injection site erythema 29 5 (46%)
Tooth loss 8 4 (36%)
Hemaglobin decreased 9 4 (36%)
Nasopharyngitis 6 4 (36%)
Rash 5 4 (36%)
Irritability 4 4 (36%)
Diarrhea 6 4 (36)
Dental caries 4 4 (36)
Adverse Events (in ≥4 Patients)
All patients reported≥1 AE during the study
AEs were reported byinvestigators asprimarily mild (73%)or moderate (21%) andunrelated to study drug(82%)
• Three SAEs were reported by investigators as possiblyrelated to study drug:– Craniosynostosis and conductive deafness (same patient)– Mild chronic hepatitis in 1 patient, confounded by
concomitant montelukast; montelukast was discontinuedand liver function tests returned to within normal range bylast assessment
• One patient died (septic shock, unrelated to study drug)at 7.5 months of treatment
1. Whyte MP et al. Asfotase alfa: Poster presented at the 2014Pediatric Academic Societies and Asian Society for PediatricResearch Joint Meeting, Vancouver, B.C., Canada, May 4, 2014.Abstract 752396. 2. Simmons J et al. Poster presented atAmerican College of Medical Genetics and Genomics NationalMeeting, Tampa, FL. March 11, 2016
Serious Adverse Events
SAE, serious adverse event
8/27/2016
18
PHASE II
Asfotase AlfaFOR
CHILDREN WITHHYPOPHOSPHATASIA
PHASE II
Asfotase AlfaFOR
CHILDREN WITHHYPOPHOSPHATASIA
• Phase II, open-label study; 1 site in USA, 1 site in Canada1-3
• Major inclusion criteria:1–3
• 5–12 years old
• Significant HPP-related skeletal disease
• Primary Endpoints:• Efficacy, safety and tolerability of asfotase alfa at 6 months
• Skeletal health assessed radiographically
Study design
1. ClinicalTrials.gov: NCT00952484; NCT01203826.2. Madson KL, et al. J Bone Miner Res. 2014:29 (Suppl 1).3. Madson KL, et al. Abstract presented at the Pediatric Academic Societies and Asian Society for Pediatric Research2014 Joint Meeting.
Extension Phase(n=12)
Endpoints: Radiographic and functionalimprovements,
growth/development, long-term safety
Initial dose: 3 mg/kg/weekIncreased to 6 mg/kg/week after 3-9 months
via protocol amendment
6Months
3Years
BL 2Years
1Year
12 patients continue treatment1 patient withdrew
3Months
4Years
5Years
Initial Phase(n=13)
Endpoints:Radiographic
improvement, safetyRandomized:
6 mg/kg/week (n=6)9 mg/kg/week (n=7)
• Major exclusion criteria:1–3
• Hypocalcemia or hypophosphatemia• Current other treatable rickets• Prior bisphosphonate treatment
Primary Outcome Objective:Improvement of Radiographic
Skeletal Disease
Primary endpoint:Radiographic Global Impression of Change (RGI-C)
• Change in ricketsseverity assessed bya 7-point scale
• Paired radiographs
• Mean score of 3independentradiologists blindedto time points afterfirst radiograph
WORSENING HEALING
0No Change
+1Minimal
+2Substantial
+3Complete or
Near
–1Mild
–2Moderate
–3Severe
Baseline 4.5 YearsRGI-C +2.0
*The primary endpoint was met (RGI-C improvement relative to historical controls at 6 months)
RGI-C scores at each visit
0
0.5
1
1.5
2
2.5
3
3 Months 6 Months 1 Year 2 Years 3 Years 4 Years 5 YearsStudy visit / Duration of treatment
12 12 12 12 8 11 12n
2.30.3
2.31.0
2.31.3
2.31.0
3.01.3
3.00.7
2.71.7
MaxMin
P < 0.01 for all time points compared with 0
+1.8
+2.0*
+1.7
+2.0 +2.0
+2.3+2.2
Med
ian
RG
I-C
Sco
re
+
+
+
+
+
+
Metaphyseal Flare
Baseline Week 24
8/27/2016
19
Physical Assessments
Hand-HeldDynamometry
• Grip• Knee flexion
• Knee extension
• Hip flexion• Hip extension
• Hip abduction
Six-Minute Walk Test BOT-2 Strength and AgilityComposite
Running Speed and Agility• 50 ft shuttle run• side step over beam• one-legged stationary hop• one-legged side hop• two-legged side hop
Strength• standing long jump• push-ups• curl-ups• wall sit• V-up
Bruininks-Oseretsky Test of Motor Proficiency, 2nd Edition(BOT-2)
Strength Test
Sit ups V-ups
Standing long jump Wall sit
Push ups
SD, standard deviationDeitz et al. Phys Occup Ther Pediatr. 2007;27:87-102
Running Speed and Agility Test
Two-legged side hop
Stepping over a balance beam
One-legged side hop
Shuttle run
Baseline
Walked 350 meters
Week 24
Walked 401 meters
6 minute walk test
Patient 4 at Baseline
8/27/2016
20
Patient 4 after 1 ½ years of Rx
Baseline
14 inches
Week 24
37 inches
Strength and Agility Composite Standard Score
119
120
8/27/2016
21
0
0.2
0.4
0.6
0.8
1
1.2
1.4
Baseline 6 Months 1 Year 2 Years 3 Years 4 Years 5 Years
Med
ian
disa
bilit
y in
dex
scor
e
Study Visit
Childhood Health Assessment Questionnaire (CHAQ):Disability Index
MCID, minimal clinically important differenceDempster H et al. Arthritis Rheum 2001;44:1768-74
2.250.0
0.50.0
2.00.0
1.750.0
1.50.0
0.880.0
1.00.0
MaxMin
P < 0.05 mean change from baseline at each time point
13 11 12 8 11 12 n123.0Maximumdisability
No disability
Decreases ≥0.13 are considered above theminimal clinically important difference (MCID) injuvenile arthritis1
Decrease: >5×MCID
8 sub-scales of age-appropriate activities of daily living
CHAQ
CHAQ and PODCI: PainPODCI
Nodiscomfort
aMean of individual patient changes from baseline compared to 0 (no change).CHAQ, Childhood Health Assessment Questionnaire; NS, non-significant; PODCI, Pediatric Outcomes Data Collection Instrument.
Safety• Transient, dose-dependent injection site
reactions in all patients which are lessprominent and less frequent with lowerdoses on the extension study
• No ENB-0040-Related SAEs
• No evidence of ectopic calcification onretinal examination or renal ultrasound
• Low Titer Anti-ENB0040 Antibodies
Lipohypertrophy
• The most common AEs were mild-to-moderate ISRs
• During treatment with asfotase alfa, improvementswere observed as early as 6 months in children for:– Strength– Running Speed and Agility– Disability– Transfer and Basic Mobility– Sports and Physical Functioning– Pain
• Improvements were sustained through 5 years oftreatment
Conclusions
8/27/2016
22
• 03 July 2015 – Japan (HPP)
• 14 August 2015 – Canada (Pediatric-Onset HPP)
• 28 August 2015 – Europe (Pediatric-Onset HPP)
• 23 October 2015– United States (Pediatric-Onset HPP)